|
[1]
|
Lazar, S. and Kahlenberg, J.M. (2023) Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. Annual Review of Medicine, 74, 339-352. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Sim, T.M., Ong, S.J., Mak, A., et al. (2022) Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bed-side. International Journal of Molecular Sciences, 23, 2505. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Bertsias, G.K. and Boumpas, D.T. (2010) Pathogenesis, Diagnosis and Management of Neuropsychiatric SLE Manifestations. Nature Reviews Rheumatology, 6, 358-367. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
(1999) The American College of Rheumatology Nomenclature and Case Definitions for Neuropsychiatric Lupus Syndromes. Arthritis & Rheumatology, 42, 599-608. [Google Scholar] [CrossRef]
|
|
[5]
|
Liu, Y., Tu, Z., Zhang, X., et al. (2022) Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus: A Review. Frontiers in Cell and Developmental Biology, 10, Article ID: 998328. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Ho, R.C., Ong, H., Thiaghu, C., et al. (2016) Genetic Variants That Are Associated with Neuropsychiatric Systemic Lupus Erythematosus. The Journal of Rheumatology, 43, 541-551. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Li, X., Xiang, X., Sun, J., et al. (2020) Prevalence, Outcome and Prognostic Factors of Neuropsychiatric Systemic Lupus Erythematosus: A Real World Single Center Study. Modern Rheumatology, 30, 321-326. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Fleetwood, T., Cantello, R. and Comi, C. (2018) Antiphos-pholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. Frontiers in Neurology, 9, 1001. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Eber, T., Chapman, J. and Shoenfeld, Y. (2005) Anti-Ribosomal P-Protein and Its Role in Psychiatric Manifestations of Systemic Lupus Erythematosus: Myth or Reality? Lupus, 14, 571-575. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Matus, S., Burgos, P.V., Bravo-Zehnder, M., et al. (2007) Antiribosomal-P Autoantibodies from Psychiatric Lupus Target a Novel Neuronal Surface Protein Causing Cal-cium Influx and Apoptosis. Journal of Experimental Medicine, 204, 3221-3234. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Magro-Checa, C., Schaarenburg, R.A., Beaart, H.J., et al. (2016) Com-plement Levels and Anti-C1q Autoantibodies in Patients with Neuropsychiatric Systemic Lupus Erythematosus. Lupus, 25, 878-888. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Jha, N., Alexander, E., Kanish, B. and Badyal, D.K. (2018) A Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Center in Punjab. Indian Dermatology Online Journal, 9, 299-303. [Google Scholar] [CrossRef]
|
|
[13]
|
Auyeung, J. and Lee, M. (2018) Successful Treatment of Stevens-Johnson Syndrome with Cyclosporine and Corticosteroid. Canadian Journal of Hospital Pharmacy, 71, 272-275. [Google Scholar] [CrossRef]
|
|
[14]
|
Tangamornsuksan, W. and Lohitnavy, M. (2018) Associa-tion between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Me-ta-Analysis. JAMA Dermatology, 154, 441-446. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Oakley, A.M. and Krishnamurthy, K. (2022) Stevens John-son Syndrome. StatPearls Publishing, Treasure Island.
|